Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives -: Eleutherin, α lapachone, and β lapachone

被引:92
作者
Krishnan, P [1 ]
Bastow, KF [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
关键词
naphthoquinones; topoisomerase II; catalytic inhibitors;
D O I
10.1016/S0006-2952(00)00437-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pyranonaphthoquinones have diverse biological activities against Gram positive bacteria, fungi and mycoplasms, and, recently, there has also been an increasing interest in their anti-cancer activity. This study includes three derivatives: eleutherin (compound 1), beta lapachone (compound 2), and its structural isomer, alpha lapachone (compound 3). The mechanism of topoisomerase II inhibition by the three derivatives was examined systematically with respect to the steps of the catalytic cycle of the enzyme. Etoposide, the prototypical enzyme poison, was used as a control and in combination with compounds 1-3 to localize their mechanism of action. The study revealed that eleutherin (1) and beta lapachone (2) inhibited topoisomerase II by inducing religation and dissociation of the enzyme from DNA in the presence of ATP. Whereas compound 2 was an "irreversible" inhibitor of topoisomerase II, compound 1 merely slowed the catalytic cycle of the enzyme. alpha Lapachone (3), on the other hand, inhibited initial non-covalent binding of topoisomerase II to DNA and, in addition, induced religation of DNA breaks (even in pre-established ternary complexes) before dissociating the enzyme from DNA. Compound 3 was an "irreversible" inhibitor of topoisomerase II. The diverse and unique mechanisms of topoisomerase II inhibition by pyranonaphthoquinone derivatives reveal novel ways to target the enzyme with potential for anti cancer drug design. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1367 / 1379
页数:13
相关论文
共 30 条
[1]   Catalytic inhibitors of DNA topoisomerase II [J].
Andoh, T ;
Ishida, R .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :155-171
[2]   Structure and mechanism of DNA topoisomerase II [J].
Berger, JM ;
Gamblin, SJ ;
Harrison, SC ;
Wang, JC .
NATURE, 1996, 379 (6562) :225-232
[3]   Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors [J].
Davies, SL ;
Bergh, J ;
Harris, AL ;
Hickson, ID .
BRITISH JOURNAL OF CANCER, 1997, 75 (06) :816-821
[4]   Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16) resistant human leukemia K562 cells [J].
Fattman, CL ;
Allan, WP ;
Hasinoff, BB ;
Yalowich, JC .
BIOCHEMICAL PHARMACOLOGY, 1996, 52 (04) :635-642
[5]  
FERGUSON PJ, 1988, CANCER RES, V48, P5956
[6]   Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage [J].
Fortune, JM ;
Osheroff, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (28) :17643-17650
[7]  
Frydman B, 1997, CANCER RES, V57, P620
[8]   EFFECTS OF BETA-LAPACHONE, A PEROXIDE-GENERATING QUINONE, ON MACROMOLECULE SYNTHESIS AND DEGRADATION IN TRYPANOSOMA-CRUZI [J].
GOIJMAN, SG ;
STOPPANI, AOM .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1985, 240 (01) :273-280
[9]  
Hara H, 1997, CHEM PHARM BULL, V45, P1714, DOI 10.1248/cpb.45.1714
[10]  
HOFFMANN GA, 1990, ANTI-CANCER DRUG DES, V5, P273